Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

MANG - Alzchem Group AG successfully completes long-term succession planning for its Management Board: Supervisory Board appoints Dr. Jurgen Sans as Chief Operating Officer with effect from 1 January 2026

Company: AlzChem Group AG Date: 2025-05-23 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details 

Corporate | 23 May 2025 09:00

#   

Alzchem Group AG successfully completes long-term succession planning for its Management Board: Supervisory Board appoints Dr. Jürgen Sans as Chief Operating Officer with effect from 1 January 2026

Alzchem Group AG / Key word(s): Personnel  

Alzchem Group AG successfully completes long-term succession planning for its Management Board: Supervisory Board appoints Dr. Jürgen Sans as Chief Operating Officer with effect from 1 January 2026  

  

23.05.2025 / 09:00 CET/CEST  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**Alzchem Group AG successfully completes long-term succession planning for its Management Board: Supervisory Board appoints Dr. Jürgen Sans as Chief Operating Officer with effect from 1 January 2026**

**Trostberg, May 23, 2025** – Alzchem Group AG, a global specialty chemicals company, has successfully completed its long-term succession planning for the Management Board.

At its meeting on May 20, 2025, the Supervisory Board unanimously resolved to appoint Dr. Jürgen Sans as Chief Operating Officer (COO) for a three-year term beginning on 1 January 2026 and ending on 31 December 2028. Dr. Sans, who holds a doctorate in chemistry and has been with Alzchem for over 27 years, previously headed the Innovation and Research & Development division. He succeeds Klaus Englmaier, who will retire at the end of 2025. Mr. Englmaier has contributed significantly to the successful development of the company and leaves behind a strong foundation for the future.

Markus Zöllner, Chairman of the Supervisory Board of Alzchem Group AG, explains: “Through his many years of service and commitment, Klaus Englmaier has made a decisive contribution to the strong market position of Alzchem Group AG as a leading specialty chemicals company. We will miss his expertise and dedication, but thanks to early succession planning, a seamless handover and continued successful development have been ensured. In Dr. Jürgen Sans, we are gaining an experienced and highly qualified colleague for the Management Board who has had a significant influence on the further development of the company through his many years of work in innovation and research & development. His comprehensive expertise will play a decisive role in leading Alzchem Group AG successfully into the future.”

With Martina Spitzer succeeding Dr. Georg Weichselbaumer, who is leaving at the end of the year, on 1 January 2025, and the appointment of Dr. Jürgen Sans, the succession plan for the Management Board is now complete. As of 1 January 2026, the Management Board of Alzchem Group AG will therefore consist of Andreas Niedermaier (CEO), Andreas Lösler (CFO), Martina Spitzer (CSO) and Dr. Jürgen Sans (COO). Together, they will continue to drive the successful development of the company and secure the profitable growth of Alzchem Group AG in the long term.

**About Alzchem**  

Alzchem is a leading international specialty chemicals company that provides sustainable solutions to global challenges such as climate change, population growth, defense, and increasing life expectancy. With its comprehensive product range, the company is often the market leader in profitable niche markets in diversified industries. It serves sectors such as human and animal nutrition and agriculture, helping to efficiently meet the growing demand for food. Its own pharmaceutical raw materials and creatine products also support healthy aging. Alzchem is also involved in renewable energies and fine chemicals, produces important raw materials for the defense industry, and guarantees a high level of independence and supply security through its “Made in Germany” production.

With around 1,700 employees at four locations in Germany, a plant in Sweden, and three sales companies in the US, China, and England, Alzchem generated sales of €554.2 million and EBITDA of €105.3 million in 2024.

  

- - -

23.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Alzchem Group AG |
|     | Dr.-Albert-Frank-Str. 32 |
|     | 83308 Trostberg |
|     | Germany |
| Phone: | +498621862888 |
| Fax: | +49862186502888 |
| E-mail: | ir@alzchem.com |
| Internet: | www.alzchem.com |
| ISIN: | DE000A2YNT30 |
| WKN: | A2YNT3 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart |
| EQS News ID: | 2144076 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | EQS News Service |

- - -

2144076  23.05.2025 CET/CEST

![](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2144076&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)